A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
This research study is testing a new medication called Eloralintide (also known as LY3841136). It's designed for adults who are overweight or have obesity but do not have type 2 diabetes. The main goal is to find out if Eloralintide can effectively help people manage their weight and if it's safe to use. Some people will receive Eloralintide, while others will receive a placebo (a dummy treatment). The study has two parts: a main phase lasting about 75 weeks, and an extended phase for those with prediabetes, which will continue for another two years. This helps researchers understand the longer-term effects of the medication.
At a glance
What is this study about?
This study is designed to investigate a new medication called Eloralintide. It's for adults who are overweight or have obesity and are looking for help with weight management, but importantly, they mustn't have type 2 diabetes. The scientists running this study want to learn two main things: first, how well Eloralintide works to help people lose weight, and second, if it's safe to use.
To do this, some people in the study will be given Eloralintide, while others will receive a placebo. A placebo looks just like the study drug but doesn't contain any active medicine. This comparison is important because it helps researchers understand if any changes are truly due to the Eloralintide or if they might have happened anyway. The study is divided into a main phase and an extension phase to get a full picture of the medication's effects.
Finding new ways to manage weight is important for many people, as being overweight or having obesity can sometimes lead to other health problems. This research could help us understand if Eloralintide could be a new option for individuals in the future.
Key takeaways
- Tests a new weight-loss medication called Eloralintide.
- For adults who are overweight or have obesity, but without type 2 diabetes.
- Compares Eloralintide against a placebo (dummy treatment).
- Study lasts about 75 weeks, with an optional extension for some.
- Aims to check both how well it works and if it's safe.
- Regular health checks throughout your participation.
Who may be eligible?
To join this study, you need to be an adult (18 or older) and fit certain health measurements. For instance, your Body Mass Index (BMI) needs to be 30 or higher. If your BMI is 27 or higher, you could also qualify if you have one of these weight-related health conditions: high blood pressure, unhealthy cholesterol levels, sleep apnea (where you stop breathing briefly during sleep), or heart disease. You also need to have tried to lose weight with diet changes before and your weight must have been stable for the three months leading up to the study.
However, some things would mean you can't take part. This includes having had or planning to have weight-loss surgery (like liposuction is okay if it was over a year ago). Similarly, if you've had certain procedures inside your gut for weight loss, you might not be eligible. You also can't have type 1 or type 2 diabetes. If you've had a recent heart attack, stroke, or other serious heart problems in the last three months, or severe heart failure, you won't be able to join. Finally, if you've used other weight-loss medications or remedies in the last three months, you won't qualify.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Is your Body Mass Index (BMI) 30 or higher, or 27 or higher with conditions like high blood pressure or sleep apnea?
- Have you tried to lose weight through dieting before?
- Have you had stable weight for the past 3 months?
- Do you NOT have type 1 or type 2 diabetes?
- Have you NOT had any major heart problems (like a heart attack or stroke) in the past 3 months?
What does participation involve?
If you decide to take part in this study, you'll be involved for about 75 weeks, which is roughly a year and a half. During this time, you'll have regular visits to the study clinic where doctors and nurses will check your health, measure your weight, and ask about your well-being. You'll be given either the study medication (Eloralintide) or a placebo, which you'll need to take as instructed.
For some participants who have 'prediabetes' (meaning their blood sugar levels are higher than normal but not yet at the level of type 2 diabetes), the study will continue for an extra two years after the main phase finishes. This 'extension phase' will help researchers understand the long-term effects of the medication in this specific group. Throughout the study, you'll be actively monitored, and you'll have scheduled appointments to ensure your safety and to track your progress.
Potential risks and benefits
Locations (169)
- MFA Clinical ResearchVerified postcodeTuscaloosa, United States· Recruiting
- Headlands Research - ScottsdaleVerified postcodeScottsdale, United States· Recruiting
- Neighborhood Healthcare Institute of HealthVerified postcodeEscondido, United States· Recruiting
- Ark Clinical Research - Fountain ValleyVerified postcodeFountain Valley, United States· Recruiting
- Desert Oasis Healthcare Medical GroupVerified postcodePalm Springs, United States· Recruiting
- Peninsula Research AssociatesVerified postcodeRolling Hills Estates, United States· Recruiting
- Care Access - SacramentoVerified postcodeSacramento, United States· Recruiting
- Southern California Clinical ResearchVerified postcodeSanta Ana, United States· Recruiting
- University Clinical Investigators, Inc.Verified postcodeTustin, United States· Recruiting
- Chase Medical Research, LLCVerified postcodeWaterbury, United States· Recruiting
- JEM Research InstituteVerified postcodeAtlantis, United States· Recruiting
- BioMed Research & Medical CenterVerified postcodeMiami, United States· Recruiting
Common questions
What is Eloralintide?
Eloralintide is a new medication being tested in this study to see if it can help adults who are overweight or have obesity manage their weight.
What is a 'placebo'?
A placebo is a 'dummy' treatment that looks just like the real medication but contains no active ingredients. It's used so researchers can compare its effects to the actual drug.
How long will the study last if I join?
The main part of the study will last about 75 weeks (around 1.5 years). If you have prediabetes, you might continue for another 2 years in an extension phase.
Can I join if I have diabetes?
No, this study is specifically for people who do not have type 1 or type 2 diabetes.
Will I know if I'm getting the real medication or the placebo?
No, during the study, neither you nor your study doctor will know whether you are receiving Eloralintide or the placebo. This is to ensure fair and unbiased results.
How to find out more
Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.